Lewis J P, Denardo G L, Denardo S J
Department of Internal Medicine, University of California Davis Medical Center 95816, USA.
Hybridoma. 1995 Apr;14(2):115-20. doi: 10.1089/hyb.1995.14.115.
B-cell malignancies, such as malignant lymphoma and chronic lymphocytic leukemia, commonly present with advanced disease and multiple sites of involvement. Consequently, systemic combination chemotherapy is the standard therapeutic approach and cures about one half of these patients. Development of novel therapies is required if the remaining patients are to be cured of their malignancy. Lym-1, a mouse monoclonal antibody that is reactive with these malignancies, has been coupled with 131I or 67Cu and used to treat 55 patients with advanced B-cell malignancies that had proven resistant to standard therapy. The majority of the patients responded to this therapy and the survival of responders was longer than that of non-responders. Similar results have recently been reported by others. These results represent a remarkable achievement for single agent therapy because these trials were exploratory in nature and most of the patients had failed many chemotherapy regimens. The toxicities were in general mild and readily manageable. It appears that enhancing strategies are likely to improve upon these results by increasing the therapeutic index.
B细胞恶性肿瘤，如恶性淋巴瘤和慢性淋巴细胞白血病，通常表现为疾病进展和多部位受累。因此，全身联合化疗是标准的治疗方法，约有一半的此类患者可被治愈。如果要治愈其余患者的恶性肿瘤，就需要开发新的治疗方法。Lym-1是一种与这些恶性肿瘤反应的小鼠单克隆抗体，已与131I或67Cu偶联，并用于治疗55例对标准治疗耐药的晚期B细胞恶性肿瘤患者。大多数患者对这种治疗有反应，有反应者的生存期比无反应者长。最近其他人也报道了类似的结果。这些结果代表了单药治疗的一项显著成就，因为这些试验本质上是探索性的，而且大多数患者已经对多种化疗方案无效。毒性一般较轻，易于控制。通过提高治疗指数，强化策略似乎有可能改善这些结果。
